Rochester Medical
Corporation ROCM today announced it has entered into a definitive
merger agreement with C. R. Bard, Inc. BCR at a price of $20 per
share, or approximately $262 million in the aggregate. The Rochester Medical
Board of Directors unanimously approved the agreement and will recommend that
the Company's shareholders approve the transaction.
Under the terms of the merger agreement, Rochester Medical shareholders will
receive $20 in cash for each share that they hold at the closing of the
merger, representing a 37 percent premium over the Company's average closing
price during the 90 trading days ended September 3, 2013. The acquisition is
subject to certain closing conditions specified in the definitive agreement,
including regulatory approvals and the approval of Rochester Medical's
shareholders. The transaction is expected to close in the fourth calendar
quarter of 2013.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in